Everolimus and lonafarnib
Phase 3Small molecule
Everolimus and lonafarnib is one of 7 small molecule programs targeting Double-blind. It is currently in Phase 3.
1
Indications
2
Total Trials
1
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
10 competitors in Double-Blind
#DrugCompanyPhaseTrials
1Olumiant
Eli LillyPhase 3
Albenza
IImpax Laboratories, LLC
Phase 3
Everolimus and lonafarnib
BBoston Children's Hospital
Phase 3
Inosine Pranobex
NNewport Pharmaceuticals International
Preclinical
PORT-77
PPortal Therapeutics, Inc.
Phase 1
Western Therapy
JJiangxi Qingfeng Pharmaceutical Co. Ltd.
Preclinical
Interferon Alfa-N3
IInterferon Sciences
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Progeria1 trial
Phase I/II Trial of Everolimus in Combination With Lonafarnib in Progeria
Unknown status·—·Phase 1/2·NCT02579044·80 enrolled
Double-blind1 trial
Double-Blind Trial of Everolimus for Improving Social Abilities in PTEN Germline Mutations
Not yet recruiting·—·Phase 2/3·NCT07218575·60 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Everolimus and lonafarnib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- BBoston Children's Hospital